MacroGenics Sells Maryland GMP Site to Bora for $122.5M
MacroGenics will sell its GMP drug substance manufacturing operations in Rockville and Frederick, Maryland—including an FDA-approved 11,000-liter facility and 140 personnel—to Bora Pharmaceuticals for a $122.5 million upfront payment. The deal establishes a supply arrangement with Bora and transfers CDMO responsibilities, freeing capital to accelerate MacroGenics’ antibody-based pipeline.
1. Transaction Overview
MacroGenics has entered a definitive agreement to sell its good manufacturing practice (GMP) drug substance operations to Bora Pharmaceuticals for an upfront payment of $122.5 million. The transaction covers the transfer of the manufacturing site, related CDMO operations, and associated personnel.
2. Facility and Workforce Transfer
The sale includes MacroGenics’ Rockville, Maryland headquarters with an FDA-approved facility offering 11,000 liters of capacity, plus a Frederick, Maryland warehouse. Approximately 140 employees supporting clinical and commercial production are expected to join Bora under the agreement.
3. Strategic Rationale
Proceeds from the sale will provide non-dilutive capital to support MacroGenics’ antibody-based therapeutic pipeline and focus resources on key clinical and regulatory milestones. MacroGenics will retain access to expanded development and manufacturing capabilities through a supply agreement with Bora.
4. Timeline and Next Steps
The transaction is subject to customary closing conditions and is expected to finalize in the third quarter of 2026. Upon closing, Bora will assume full CDMO responsibilities while MacroGenics transitions to a customer under the new supply arrangement.